Literature DB >> 35923613

A Machine Learning Model Based on Health Records for Predicting Recurrence After Microwave Ablation of Hepatocellular Carcinoma.

Chao An1, Hongcai Yang1,2, Xiaoling Yu1, Zhi-Yu Han1, Zhigang Cheng1, Fangyi Liu1, Jianping Dou1, Bing Li3, Yansheng Li4, Yichao Li4, Jie Yu1, Ping Liang1.   

Abstract

Background and Aim: Early recurrence (ER) presents a challenge for the survival prognosis of patients with hepatocellular carcinoma (HCC). The aim of this study was to investigate machine learning (ML) models using clinical data for predicting ER after microwave ablation (MWA).
Methods: Between August 2005 and December 2019, 1574 patients with early-stage HCC underwent MWA at four hospitals were reviewed. Then, 36 clinical data points per patient were collected, and the patients were assigned to the training, internal, and external validation set. Apart from traditional logistic regression (LR), three ML models-random forest, support vector machine, and eXtreme Gradient Boosting (XGBoost)-were built and validated for their predictive ability with the area under ROC curve (AUC). Algorithms such as SHapley Additive exPlanations (SHAP) and local interpretable model-agnostic explanations (LIME) were used to realize their interpretability.
Results: The three ML models all outperformed LR (P < 0.001 for all) in predictive ability. When nine variables (tumor number, platelet, α-fetoprotein, comorbidity score, white blood cell, cholinesterase, prothrombin time, neutrophils, and etiology) were extracted simultaneously using recursive feature elimination with cross-validation, the XGBoost model achieved the best discrimination among all models, with an AUC value 0.75 (95% CI [confidence interval]: 0.72-0.78) in the training set, 0.74 (95% CI: 0.69-0.80) in the internal validation set, and 0.76 (95% CI: 0.70-0.82) in the external validation set, and it was interpreted depending on the visualization of risk factors by the SHAP and LIME algorithms. The predictive system of post-ablation recurrence risk stratification was provided on online (http://114.251.235.51:8001/) based on XGboost analysis.
Conclusion: The XGBoost model based on clinical data can effectively predict ER risk after MWA, which can contribute to surveillance, prevention, and treatment strategies for HCC.
© 2022 An et al.

Entities:  

Keywords:  hepatocellular carcinoma; machine learning; microwave ablation; recurrence; risk stratification

Year:  2022        PMID: 35923613      PMCID: PMC9342890          DOI: 10.2147/JHC.S358197

Source DB:  PubMed          Journal:  J Hepatocell Carcinoma        ISSN: 2253-5969


  32 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

2.  Machine Learning-Based Model for Prediction of Outcomes in Acute Stroke.

Authors:  JoonNyung Heo; Jihoon G Yoon; Hyungjong Park; Young Dae Kim; Hyo Suk Nam; Ji Hoe Heo
Journal:  Stroke       Date:  2019-05       Impact factor: 7.914

3.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

4.  Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy.

Authors:  Tingyu Chen; Xiang Li; Yingxue Li; Eryu Xia; Yong Qin; Shaoshan Liang; Feng Xu; Dandan Liang; Caihong Zeng; Zhihong Liu
Journal:  Am J Kidney Dis       Date:  2019-04-25       Impact factor: 8.860

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

6.  Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3-<5 cm.

Authors:  Mohamed M A Zaitoun; Saeed B Elsayed; Nahla A Zaitoun; Radwa K Soliman; Ali H Elmokadem; Alaa A Farag; Mahmoud Amer; Ali M Hendi; Nader E M Mahmoud; Dalia Salah El Deen; Ahmed M Alsowey; Shahenda Shahin; Mohammad Abd Alkhalik Basha
Journal:  Int J Hyperthermia       Date:  2021       Impact factor: 3.914

7.  Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival.

Authors:  Yi Yang; Yi Chen; Feng Ye; Xiaojing Cao; Yujing Xin; Yanan Wang; Yong Lei; Xiao Li; Duiping Feng; Xiang Zhou; Qingsheng Fan
Journal:  Eur Radiol       Date:  2020-11-11       Impact factor: 5.315

Review 8.  From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.

Authors:  Dimitrios Dimitroulis; Christos Damaskos; Serena Valsami; Spyridon Davakis; Nikolaos Garmpis; Eleftherios Spartalis; Antonios Athanasiou; Demetrios Moris; Stratigoula Sakellariou; Stylianos Kykalos; Gerasimos Tsourouflis; Anna Garmpi; Ioanna Delladetsima; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

Review 9.  Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?

Authors:  Zhi-Min Zou; De-Hua Chang; Hui Liu; Yu-Dong Xiao
Journal:  Insights Imaging       Date:  2021-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.